Ticker Details
Celldex Therapeutics, Inc. Celldex Therapeutics Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
IPO Date:	March 26, 1990
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.06B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 3.41%
Avg Daily Range (30 D):	$0.76 | 2.31%
Avg Daily Range (90 D):	$0.71 | 2.22%

Institutional Daily Volume
Avg Daily Volume:	.51M
Avg Daily Volume (30 D):	.84M
Avg Daily Volume (90 D):	.78M

Trade Size
Avg Trade Size (Sh.):	92
Avg Trade Size (Sh.) (30 D):	68
Avg Trade Size (Sh.) (90 D):	59

Institutional Trades
Total Institutional Trades:	4,988
Avg Institutional Trade:	$2.18M
Avg Institutional Trade (30 D):	$4.34M
Avg Institutional Trade (90 D):	$3.82M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.02M
Avg Closing Trade (30 D):	$8.38M
Avg Closing Trade (90 D):	$6.52M
Avg Closing Volume:	83.88K

News

Jun 14, 2026 @ 2:21 PM Celldex Presents Long-Term Barzolvolimab Results D... Source: Na

Jun 14, 2026 @ 9:15 AM Celldex Presents Positive First-in-Human Results f... Source: Na

Apr 6, 2026 @ 2:53 PM Celldex Therapeutics Announces Closing of Public O... Source: Celldex Therapeutics, Inc.

Apr 2, 2026 @ 1:48 AM Celldex Announces Pricing of $300 Million Public O... Source: Na

Mar 1, 2026 @ 2:45 PM Celldex Presents Positive Data Demonstrating Barzo... Source: Celldex

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-4.27	$-1.18	$-1.23
Diluted EPS	$-4.27	$-1.18	$-1.23
Revenue	$.87M	$.02M	$.12M
Gross Profit
Net Income / Loss	$-283.65M	$-78.69M	$-81.32M
Operating Income / Loss	$-309.06M	$-84.44M	$-87.15M
Cost of Revenue
Net Cash Flow	$18.59M	$6.86M	$-7.17M
PE Ratio

Splits
Feb 11, 2019	1:15
Mar 10, 2008	1:12
Mar 07, 2008	1:12